Hypercoagulable state, secondary; Thrombophilia; ICD-10-CM D68.69 is grouped within Diagnostic Related Group(s) (MS-DRG v 38.0): 814 Reticuloendothelial and immunity disorders with mcc; 815 Reticuloendothelial and immunity disorders with cc; 816 Reticuloendothelial and immunity disorders without cc/mcc; Convert D68.69 to ICD-9-CM. Code History
Hypercoagulable state (tendency to form clots) Protein c deficiency disease; Protein s deficiency disease; Clinical Information. A disorder of hemostasis in which there is a tendency for the occurrence of thrombosis. A rare disorder characterized by the presence of low levels of antithrombin iii which prohibits the formation of blood clots.
This is the American ICD-10-CM version of D68.9 - other international versions of ICD-10 D68.9 may differ. A condition in which there is a deviation from or interruption of the normal coagulation properties of the blood.
Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status Z92.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z92.81 became effective on October 1, 2021.
59.
Yes, ICD 10 code D68. 69 (Other thrombophilia) groups multiple ICD 9 code descriptors within this category including secondary hypercoagulable state (previously 289.82).
Hypercoagulability describes the pathologic state of exaggerated coagulation or coagulation in the absence of bleeding. Arterial thrombosis, such as in myocardial infarction and stroke, is different from venous thromboses, such as deep venous thrombosis (DVT) and pulmonary embolism (PE).
Secondary hypercoagulable states are primarily acquired disorders that. predispose to thrombosis through complex and multifactorial mechanisms. These involve blood flow abnormalities or defects in blood composition and of. vessel walls.
A useful mnemonic for the common causes of hypercoagulability is CALMSHAPES: protein C deficiency, Antiphospholipid antibody syndrome, factor V Leiden; Malignancy, protein S deficiency, Homocystinemia, Antithrombin deficiency, Prothrombin G20210A, increased factor VIII (Eight), Sticky platelet syndrome.
Abstract. It is well known that atrial fibrillation is associated with high incidence of thromboembolic events, propably due to a prothrombotic or hypercoagulable state.
Diagnosis of hypercoagulability can include blood tests to look at the levels of anticoagulant proteins, as well as genetic testing to identify the most common inherited thrombophilias.
Based on current knowledge, antiphospholipid syndrome is the most prevalent hypercoagulable state, followed by factor V Leiden (FVL) mutation, prothrombin gene G20210A mutations, elevated factor VIII, and hyperhomocysteinemia. Less common disorders include deficiencies in antithrombin, protein C, or protein S.
CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
Title XVIII of the Social Security Act, ยง1833 (e) prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.
The information in this article contains billing, coding or other guidelines that complement the Local Coverage Determination (LCD) for MolDX: Genetic Testing for Hypoercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) L36400.
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.